Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00873223 · ClinicalTrials.gov registry record · Phase 1
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00873223 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 33 participants.
The verdict
NCT00873223, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir
Interventions
- DRUG liraglutide
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00873223
The ClinicalTrials.gov registry entry for NCT00873223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which liraglutide is the first listed.
NCT00873223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00873223 about?
NCT00873223 is a clinical study titled "Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir". This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir
What is the current status of trial NCT00873223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00873223?
The interventions under investigation include: liraglutide (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00873223?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.